Advertisement

International Cancer Conference Journal

, Volume 6, Issue 1, pp 25–28 | Cite as

Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma

  • Mitsutaka Onoda
  • Ryo Sugimoto
  • Noriyuki Uesugi
  • Misato Takayama
  • Ei Shiomi
  • Renpei Kato
  • Yoichiro Kato
  • Ryo Takata
  • So Omori
  • Wataru Obara
Case report

Abstract

Squamous cell carcinoma of the prostate is a rare tumor. It has been typically described as an aggressive cancer, with a median survival time of 14 months. We present a case of locally advanced squamous cell carcinoma of the prostate with a regional lymph node metastasis. The patient received a novel combination chemotherapy regimen, docetaxel, cisplatin, and 5-fluorouracil, with radiotherapy to the whole pelvis and prostate. He was subsequently treated with seven courses of docetaxel, cisplatin, and 5-fluorouracil chemotherapy without any severe adverse events. We identified a 60.1 % reduction in the prostatic tumor, and the lymph node metastasis was shrunk after chemotherapy. A needle biopsy of the prostate after chemotherapy revealed no malignancy. No recurrence has been observed for 24 months. A combination of docetaxel, cisplatin, and 5-fluorouracil chemotherapy and radiotherapy might be an effective therapy for squamous cell carcinoma of the prostate.

Keywords

Squamous cell carcinoma Prostate Docetaxel Cisplatin Fluorouracil 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

References

  1. 1.
    Mott LJ (1979) Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. J Urol 121:833–835PubMedGoogle Scholar
  2. 2.
    Moskovitz B, Munichor M, Bolkier M et al (1993) Squamous cell carcinoma of the prostate. Urol Int 51:181–183CrossRefPubMedGoogle Scholar
  3. 3.
    Malik RD, Dakwar G, Hardee ME et al (2011) Squamous cell carcinoma of the prostate. Rev Urol 13:56–60PubMedPubMedCentralGoogle Scholar
  4. 4.
    Sarma DP, Weilbaecher TG, Moon TD (1991) Squamous cell carcinoma of prostate. Urology 37:260–262CrossRefPubMedGoogle Scholar
  5. 5.
    Munoz F, Franco P, Ciammella P et al (2007) Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat Oncol 2:15CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Uchibayashi T, Hisazumi H, Hasegawa M et al (1997) Squamous cell carcinoma of the prostate. Scand J Urol Nephrol 31:223–224CrossRefPubMedGoogle Scholar
  7. 7.
    Okada E, Kamizaki H (2000) Primary squamous cell carcinoma of the prostate. Int J Urol 7:347–350CrossRefPubMedGoogle Scholar
  8. 8.
    Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Culine S, El-Demery M, Lamy PJ et al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848 (discussion 8) CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2016

Authors and Affiliations

  • Mitsutaka Onoda
    • 1
  • Ryo Sugimoto
    • 2
  • Noriyuki Uesugi
    • 2
  • Misato Takayama
    • 1
  • Ei Shiomi
    • 1
  • Renpei Kato
    • 1
  • Yoichiro Kato
    • 1
  • Ryo Takata
    • 1
  • So Omori
    • 1
  • Wataru Obara
    • 1
  1. 1.Department of UrologyIwate Medical University School of MedicineMoriokaJapan
  2. 2.Department of Molecular Diagnostic PathologyIwate Medical University School of MedicineMoriokaJapan

Personalised recommendations